Angiosarcoma is a rare and aggressive malignant neoplasm that arises from endothelial cells of blood or lymphatic vessels, ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Under the agreement terms, Alumis will receive $40 million in upfront and near-term co-development payments, with the possibility of an additional $140 million in milestone and field option payments.

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

A 71-year-old man visited his doctor about a widespread rash on his upper face and scalp that developed 2-3 months prior. On ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...